Healthcare Industry News: Zimmer
News Release - February 10, 2015
Biomet Announces Successful Global Introduction of G7 OsseoTi Porous Acetabular ShellsWARSAW, Ind.--(Healthcare Sales & Marketing Network)--Biomet Orthopedics, LLC, a global leader in the manufacture of orthopedic and biotechnology products, today announced regulatory clearance and first clinical use of OsseoTi Porous Technology for total hip arthroplasty. CE mark and FDA clearance were achieved in November and December 2014, respectively, with first clinical use also performed in Europe in December 2014. The G7 OsseoTi shell is used in conjunction with Biomet's G7 Acetabular System, a multi-bearing acetabular platform designed to deliver simplicity, efficiency and performance for primary and revision hip arthroplasty.
Through the use of a proprietary manufacturing process, OsseoTi Porous Technology uses human CT data, in combination with 3D printing technology, to build a structure that directly mimics the architecture of human cancellous bone. This process generates a single porous architecture that allows creation of complex shapes, while maintaining the consistent porosity and strength necessary to facilitate bone and tissue ingrowth and implant stability.1* When applied to the G7 Acetabular System, this provides surgeons the benefits of highly porous technology in combination with a sizing rationale designed for hip stability.
The addition of OsseoTi Porous Technology to the G7 Acetabular System expands Biomet’s well-established portfolio of total hip constructs that combine rich clinical heritage with modern technological advancements.
1. Gupta, G. OsseoTi Porous Metal for Enhanced Bone Integration: an Animal Study. Biomet Form No. BMET0718.1-GBL.
*Animal studies are not necessarily indicative of clinical performance.
Biomet, Inc. and its subsidiaries design, manufacture and market surgical and non-surgical products used primarily by orthopedic surgeons and other musculoskeletal medical specialists. Biomet's product portfolio includes hip and knee reconstructive products; sports medicine, extremities and trauma products; spine, bone healing and microfixation products; dental reconstructive products; and cement, biologics and other products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements are often indicated by the use of words such as “will,” “intend,” “anticipate,” “estimate,” “expect,” “plan” and similar expressions. Forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from those contemplated by the forward looking statements due to, among others, the following factors: the ability of the LVB Acquisition Inc. (“LVB”), the parent of the Company, and Zimmer Holdings, Inc. (“Zimmer”) to complete their proposed merger; LVB’s and Zimmer’s ability to obtain regulatory approvals of the proposed merger on the contemplated terms and schedule; the impact of the announcement of, or failure to complete, the proposed merger on relationships with distributors, employees, customers and suppliers; the success of the Company’s principal product lines; the results of the ongoing investigation by the United States Department of Justice; the ability to successfully implement new technologies; the Company’s ability to sustain sales and earnings growth; the Company’s success in achieving timely approval or clearance of its products with domestic and foreign regulatory entities; the impact to the business as a result of compliance with federal, state and foreign governmental regulations and with the Deferred Prosecution Agreement; the impact to the business as a result of the economic downturn in both foreign and domestic markets; the impact of federal health care reform; the impact of anticipated changes in the musculoskeletal industry and the ability of the Company to react to and capitalize on those changes; the ability of the Company to successfully implement its desired organizational changes and cost-saving initiatives; the ability of the Company to successfully integrate acquisitions; the impact to the business as a result of the Company’s significant international operations, including, among others, with respect to foreign currency fluctuations and the success of the Company’s transition of certain manufacturing operations to China; the impact of the Company’s managerial changes; the ability of the Company’s customers to receive adequate levels of reimbursement from third-party payors; the Company’s ability to maintain its existing intellectual property rights and obtain future intellectual property rights; the impact to the business as a result of cost containment efforts of group purchasing organizations; the Company’s ability to retain existing independent sales agents for its products; the impact of product liability litigation losses; and other factors set forth in the Company’s filings with the SEC, including the Company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although the Company believes that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or non-occurrence of future events. There can be no assurance as to the accuracy of forward-looking statements contained in this press release. The inclusion of a forward-looking statement herein should not be regarded as a representation by the Company that the Company’s objectives will be achieved. The Company undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements which speak only as of the date on which they were made.
All trademarks herein are the property of Biomet, Inc., or its subsidiaries, unless otherwise indicated.
Source: Biomet Orthopedics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.